Compare Coinbase Global, Inc. (COIN) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Twist Bioscience Corp — how do they compare? Coinbase Global, Inc. trades at $180.01 (market cap $45.38B), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Coinbase Global, Inc. is far larger — about 4.5× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Twist Bioscience Corp for 27 Days on average.
| COIN | TWST | |
|---|---|---|
Market Cap | $45.38B | $10.08B |
Volume | 11,013,940 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $387.00 | $205.00 |
52-Week Low | $141.09 | $25.45 |
Typical Hold Time | 78 Days | 27 Days |
Enterprise Value | $43.03B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $179.39, up 0.53% today, with a bullish technical signal despite recent earnings misses. Revenue grew to $7.18B in 2025, but net income margin turned negative at -15.72%. The company maintains strong cash flow from operations at $2.43B and holds $9.55B in cash. Recent CFTC approval for derivatives clearing and expanded Citigroup partnership signal strategic expansion.
Outlook remains mixed with 55% analyst buy ratings and a $211.91 price target, but negative profitability and projected 2026 net loss of -$988M pose significant risks. Stock performance hinges on execution in derivatives and stablecoin initiatives amid volatile crypto markets.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
